Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

Azenta posts modest revenue growth but swings to a large GAAP loss in 2026.

What the company is saying

Azenta, Inc. emphasizes steady revenue growth, reporting a 5% year-over-year increase in both Q4 and full-year 2026 revenue from continuing operations, reaching $167 million and $622 million respectively. The company highlights its segment performance, with Sample Management Solutions up 9% in Q4 and 6% for the year, while Multiomics remains flat in Q4 and up 3% for the year. Management, led by Interim President and CEO Dr. Martin Madaus, frames the narrative around operational improvements, cost structure streamlining, and strategic investments aimed at turning Multiomics into a growth engine. The announcement stresses the completion of the B Medical Systems divestiture and the redeployment of capital into gene synthesis capabilities via the Elegen agreements and SynPlexity acquisition. Forward-looking guidance is optimistic, projecting fiscal 2027 revenue of $648–$660 million, organic growth of 3%–5%, and adjusted EBITDA margin expansion of 200–250 basis points, despite a 100 basis point dilution from recent deals. The tone is confident about integration and commercialization of new capabilities, while downplaying the sharp decline in GAAP profitability.

What the data suggests

The data shows revenue from continuing operations grew 5% year over year in both Q4 ($167 million) and FY 2026 ($622 million), with organic growth at 2%. Sample Management Solutions outperformed, rising 9% in Q4 and 6% for the year, while Multiomics was flat in Q4 and up 3% for the year. GAAP profitability deteriorated sharply: diluted EPS from continuing operations dropped from $0.53 in FY 2025 to ($3.50) in FY 2026, and total diluted EPS fell to ($3.70) from ($1.22). Adjusted diluted EPS for the year slipped from $0.51 to $0.48, and adjusted EBITDA margin declined to 9.4%. Operating loss for the year was $174.7 million, driven by a $149 million goodwill impairment and higher R&D expenses. Free cash flow for FY 2026 was $27 million, with $506 million in cash and equivalents at year-end. Strategic investments included $23 million in fixed license payments to Elegen, a $15 million base purchase for SynPlexity (plus up to $10 million contingent), and $118.2 million in share repurchases. FY 2027 guidance projects revenue of $648–$660 million, organic growth of 3%–5%, and a 25% improvement in free cash flow, but these are forward-looking and not yet realised.

Analysis

The announcement provides a balanced and factual summary of realised financial results for Q4 and fiscal 2026, including revenue, segment performance, cash flow, and both GAAP and non-GAAP profitability metrics. However, the tone is somewhat optimistic regarding the impact of recent acquisitions and licensing deals, with forward-looking statements about revenue, margin, and free cash flow improvements in fiscal 2027. While the company discloses large capital outlays for the Elegen and SynPlexity transactions, the benefits from these investments are projected and not yet realised. The guidance for 2027 is specific but remains an expectation, not a commitment, and is subject to execution risk. The swing to a large GAAP loss in 2026 is downplayed relative to the focus on adjusted metrics and future integration benefits. Overall, the narrative is only moderately inflated, as most claims are supported by disclosed data, but the forward-looking optimism about integration and financial improvement is not yet substantiated by realised results.

Risk flags

• ●GAAP profitability has deteriorated sharply, with a swing from $0.53 diluted EPS in FY 2025 to ($3.50) in FY 2026, and an operating loss of $174.7 million. This raises concerns about the sustainability of earnings and the impact of non-cash charges such as the $149 million goodwill impairment.
• ●The company is committing significant capital to new gene synthesis capabilities, with $23 million in fixed license payments to Elegen, a $15 million base purchase for SynPlexity, and up to $10 million in contingent consideration. The return on these investments is not yet proven, and integration risks remain.
• ●Forward-looking guidance for FY 2027 projects revenue growth, margin expansion, and improved free cash flow, but these targets depend on successful integration and commercialization of recent acquisitions, which may face operational or market challenges.
• ●Adjusted EBITDA margin and adjusted EPS have declined or stagnated, while GAAP results have worsened, indicating reliance on non-GAAP adjustments to present a more favorable picture. This divergence could mask underlying operational issues if not addressed.
• ●Share repurchases totaled $118.2 million in FY 2026, reducing cash available for operations or further investment, and $131.8 million remains authorized. If profitability does not recover, continued buybacks could constrain financial flexibility.

Bottom line

Azenta delivered modest revenue growth in 2026 but suffered a major swing to GAAP losses, driven by a large goodwill impairment and rising expenses. The company is redeploying capital from its B Medical Systems sale into gene synthesis, with substantial outlays for Elegen and SynPlexity, but the payoff from these investments is not yet visible in the numbers. Management projects stronger revenue, margin, and cash flow for 2027, but these are contingent on successful integration and market adoption of new capabilities. The divergence between adjusted and GAAP results, along with heavy capital commitments, heightens execution and financial risk. Investors should focus on whether the company can translate these investments into tangible profitability improvements in the coming quarters. The most important takeaway is that while growth investments are underway, Azenta must demonstrate a credible path back to sustained GAAP profitability.

Announcement summary

(NASDAQ:AZTA) Azenta, Inc. reported financial results for the fourth quarter and fiscal year ended September 30, 2026. For Q4 2026, revenue from continuing operations was $167 million, up 5% year over year, with organic growth of 2%. Sample Management Solutions revenue for the quarter was $94 million, up 9% year over year, while Multiomics revenue was $73 million, flat year over year. Diluted EPS from continuing operations for Q4 was $0.14, compared to $1.12 in Q4 2025, and total diluted EPS was $0.16, compared to $1.11 a year ago. Adjusted diluted EPS from continuing operations was $0.28, up from $0.21 in the prior year quarter. Adjusted EBITDA for Q4 was $19.4 million, with an adjusted EBITDA margin of 11.6%. For the full fiscal year 2026, revenue from continuing operations was $622 million, up 5% year over year, with organic growth of 2%. Sample Management Solutions revenue for the year was $344 million, up 6%, and Multiomics revenue was $277 million, up 3%. Diluted EPS from continuing operations for the year was ($3.50), compared to $0.53 in fiscal 2025, and total diluted EPS was ($3.70), compared to ($1.22) a year ago. Adjusted diluted EPS for the year was $0.48, compared to $0.51 in the prior year. Adjusted EBITDA for the year was $58.3 million, with an adjusted EBITDA margin of 9.4%. The company ended fiscal 2026 with $506 million in cash, cash equivalents, restricted cash, and marketable securities. Operating cash flow for the year was $58 million, capital expenditures were $30 million, and free cash flow was $27 million. On July 1, 2026, Azenta completed the sale of B Medical Systems and received full repayment of the $35 million vendor loan, with accrued interest, on September 3, 2026. On October 28, 2026, Azenta entered into agreements with Elegen Corp., obtaining an exclusive, royalty-free license to certain gene synthesis and cell-free cloning technologies for an initial five-year term, requiring fixed license payments totaling $23.0 million, with an option to convert to a perpetual license for $25.0 million plus unpaid fees. Aggregate capital deployment under the Elegen agreements is expected to range from $32.0 million to $71.0 million. Also on October 28, 2026, Azenta acquired SynPlexity Inc. for a base purchase price of $15.0 million in cash, with $2.5 million held back, and up to $10.0 million in contingent consideration based on revenue milestones through September 30, 2029. During fiscal 2026, Azenta repurchased 4.4 million shares of common stock for $118.2 million under its 2025 Repurchase Program, with $131.8 million remaining authorized for future repurchases as of September 30, 2026. For fiscal 2027, Azenta expects reported revenue from continuing operations to range from $648 to $660 million, with organic revenue growth of 3% to 5% year over year. Adjusted EBITDA margin is expected to expand by 200 to 250 basis points year over year, inclusive of a 100 basis point dilution from the Elegen and SynPlexity transactions. Free cash flow is expected to improve by approximately 25% relative to fiscal 2026. The company expects fiscal 2027 to focus on integration, scale-up, and commercialization of new capabilities from recent investments.

Disagree with this article?